# A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

> **NCT06405425** · PHASE2 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 52 (estimated)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** BL-B01D1
- **DRUG:** PD-1

## Key facts

- **NCT ID:** NCT06405425
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-29
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06405425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06405425, "A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06405425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*